Life Insurance with Multiple Myeloma 2026: Underwriting, Rates & Approval Options
A multiple myeloma diagnosis changes how you think about the future — and it also changes how life insurance companies look at your application. The good news is that life insurance with multiple myeloma is possible in 2026. Outcomes for myeloma patients have improved dramatically over the past two decades, and modern underwriters evaluate plasma cell disorders with far more nuance than the flat declines of the past. Whether you are newly diagnosed, in active treatment, or years into remission, there is usually a path to coverage — it just depends on timing, staging, and the carrier you choose.
This guide explains exactly what underwriters examine, how multiple myeloma affects your rate class, and which strategies give you the best chance of an affordable, approved policy in 2026.
What Is Multiple Myeloma and Why It Matters to Insurers
Multiple myeloma is a cancer of plasma cells — the white blood cells that normally produce antibodies. In myeloma, abnormal plasma cells multiply in the bone marrow, crowd out healthy blood cells, and produce an abnormal protein called M-protein (monoclonal protein). This can lead to bone lesions, kidney damage, anemia, and a weakened immune system.
For a life insurance underwriter, multiple myeloma is a serious condition because it directly affects mortality risk. However, that risk is not uniform. A person diagnosed with smoldering myeloma who is under watchful waiting looks very different on paper from someone with active, symptomatic disease who has required stem cell transplant. Insurers price each of these scenarios differently, which is why a single “yes or no” answer does not capture the reality of myeloma underwriting.
How Underwriters Evaluate a Multiple Myeloma History
Underwriters do not simply check a box that says “multiple myeloma.” They dig into the specifics of your case. The following factors move the needle the most on your application.
- Stage at diagnosis. Smoldering or Stage I disease with no symptoms is viewed far more favorably than Stage III disease with organ damage.
- Treatment response. A complete response to treatment — often measured by M-protein levels falling to undetectable — is a strong positive signal.
- Time since treatment ended. This is frequently the single most important factor. Insurers measure remission from the date active treatment ended, not the diagnosis date.
- Current M-protein levels. Stable or undetectable levels support a better rate class than rising or persistent protein.
- Complications. Kidney impairment, bone lesions, anemia, or recurrent infections all raise the rating.
- Age and overall health. A younger applicant with clean labs and no comorbidities is priced more favorably than an older applicant with multiple conditions.
Because myeloma survival has nearly doubled since the mid-1990s — climbing from roughly 32% to about 62% — carriers increasingly recognize that many patients live well for many years. That shift in the actuarial picture is exactly why more applicants with a myeloma history are being approved today rather than declined outright.
Multiple Myeloma and MGUS: The Watch-and-Wait Distinction
A related condition, monoclonal gammopathy of undetermined significance (MGUS), produces the same M-protein spike but is not cancer and does not require treatment. Some applicants discover an M-protein finding on a routine blood test and are referred to an oncologist for monitoring. This creates a common underwriting sticking point.
Because MGUS can progress to multiple myeloma in a minority of cases, many carriers impose a postponement — often two years from the date of the abnormal finding — before they will consider an offer. If your lab work is simply indicative of MGUS and no myeloma diagnosis has been made, the best move is to document stability over time and reapply once the postponement window closes. Working with an independent broker who can present the full picture is essential here, because guidelines vary widely from carrier to carrier.
Approval Odds by Remission Timeline
The chart below summarizes how a multiple myeloma history typically maps to underwriting outcomes. Every carrier is different, but this gives you a realistic starting expectation for 2026.
| Time Since Active Treatment Ended | Typical Underwriting Outcome |
|---|---|
| Currently in active treatment | Traditional policies generally unavailable; limited to guaranteed issue or employer group coverage |
| Less than 2 years | Very limited options; high premiums; guaranteed issue or simplified issue may be the only path |
| 2 to 5 years | Some carriers consider term policies; exclusions or table ratings are common |
| 5 to 10 years | More carriers consider standard term or whole life; rates begin to normalize |
| 10+ years in remission | Best rates and broadest access; many carriers treat applicants as near-standard risk |
How Multiple Myeloma Affects Your Premium
When a health condition increases risk, carriers use table ratings to price it. Each table adds roughly 25% to the standard premium. Table 1 adds about 25%, Table 2 adds 50%, Table 4 doubles the rate, and Table 6 adds 150%. The table you receive depends on your stage, remission time, and lab results.
Here is how a $500,000 20-year term policy can shift for a 45-year-old man in good overall health but with a myeloma history, using 2026 market averages:
| Rate Class | Estimated Monthly Premium ($500,000 / 20-Year Term) | Relative Cost |
|---|---|---|
| Standard (no rating) | $62/mo | Baseline |
| Table 2 (+50%) | $93/mo | 1.5x |
| Table 4 (+100%) | $124/mo | 2.0x |
| Table 6 (+150%) | $155/mo | 2.5x |
Note that a table rating is an offer — not a decline. Many applicants with a well-managed myeloma history receive a rating and accept coverage at a cost that still protects their family. The difference between a Table 2 and Table 4 rating can mean thousands of dollars over the life of the policy, which is why shopping across multiple carriers matters so much.
Coverage Options If Traditional Underwriting Is Difficult
If your myeloma history makes fully underwritten coverage unavailable right now, you still have several alternatives. Each trades cost or coverage amount for easier approval.
Compare Free Life Insurance Quotes
Answer a few questions and see personalized rates from 50+ carriers in about two minutes. No obligation.
Secure form — your information is encrypted and never sold.
- Simplified issue life insurance. No medical exam and no blood work — just a short health questionnaire. Face amounts typically range from $5,000 to $50,000, and coverage can begin immediately. This is often the strongest option for applicants in recent remission who avoid high-dose complications.
- Guaranteed issue life insurance. No health questions at all. Everyone qualifies, but coverage caps around $25,000 to $50,000, premiums are the highest per dollar, and a graded death benefit applies for the first two to three years.
- Employer or union group life. Group coverage often requires no individual medical underwriting for base amounts and can supplement an individual policy.
- Existing policies. If you bought coverage before your diagnosis, keep paying those premiums. A lapse is the single biggest financial mistake a myeloma patient can make.
Which Carriers Are Most Flexible with Myeloma Histories?
Underwriting guidelines for cancer histories vary enormously between carriers. These companies are commonly cited by brokers as the most flexible for cancer survivors and high-risk applicants in 2026.
| Carrier | Strength for Myeloma & Cancer Histories |
|---|---|
| Prudential | Known for taking on higher-risk applicants other carriers decline |
| Mutual of Omaha | Strong guaranteed issue and simplified issue options for older or higher-risk applicants |
| Transamerica | Broad table-rating flexibility, especially for older applicants |
| Physicians Mutual | No-exam coverage up to $30,000 for ages 45 to 85 |
| Gerber Life | Guaranteed issue final expense; no medical questions |
| Pacific Life | No-exam program with coverage up to $3 million for qualifying applicants |
Steps to Improve Your Approval Odds
If you are planning to apply for life insurance with a myeloma history, the order and timing of your steps matter. Follow this sequence.
- Wait until your remission window is favorable. If you are within two years of active treatment, ask whether a postponement applies and reapply once it clears.
- Gather complete medical records. Underwriters will request treatment records and may consult oncology specialists. Respond quickly to requests to avoid delays.
- Document your response to treatment. Undetectable or stable M-protein levels, clean labs, and consistent follow-up care are your strongest assets.
- Use a preliminary inquiry. A broker can gauge carrier interest without a formal application, avoiding a damaging trail of declines.
- Shop across many carriers. The same myeloma profile can be rated two to four tables apart depending on the company.
- Verify the carrier’s financial strength. Always confirm an insurer’s AM Best rating before signing.
Why This Matters to Your Family
A myeloma diagnosis often comes with real financial strain — treatment costs, time away from work, and uncertainty about the future. Life insurance is not about you; it is about making sure the people who depend on you are not left to absorb your final expenses and lost income on top of their grief. Even a modest policy creates breathing room during the hardest time your family may ever face. If cost is a concern, a smaller face amount on a rating you can afford is almost always better than no coverage at all.
It is also worth reviewing your beneficiary designations and, if you own a business, considering how a myeloma history intersects with your key person coverage. Finally, keep in mind that a critical illness rider may pay a living benefit upon diagnosis of certain conditions — a feature worth discussing with your agent as part of an overall plan. Learn more in our guide to the critical illness rider.
Frequently Asked Questions
Can I get life insurance after a multiple myeloma diagnosis?
Yes, in many cases. Applicants with a myeloma history in remission are frequently approved at table-rated premiums through traditional underwriting, while those in active treatment may qualify for simplified issue or guaranteed issue coverage. The key variables are stage, treatment response, and time since active treatment ended.
How much more will I pay with a multiple myeloma history?
Most applicants pay 50% to 150% above standard rates, depending on how long they have been in remission and how stable their labs are. Each table rating adds about 25%, and different carriers can rate the same profile two to four tables apart, so shopping multiple companies is essential.
Does MGUS disqualify me from life insurance?
MGUS itself does not automatically disqualify you, but many carriers impose a two-year postponement from the date of the abnormal M-protein finding. Once you can show stability over time, coverage options improve considerably.
Should I let an existing policy lapse after diagnosis?
No. If you already own life insurance, keeping it in force is almost always the right decision. Your existing policy is not re-underwritten because of a new diagnosis, so a lapse would mean losing coverage you may not be able to replace at the same price.
What face amount can I realistically get?
That depends on your remission status and the product type. Fully underwritten term coverage can reach $500,000 or more for applicants with a longer remission, while simplified issue policies typically cap around $50,000 and guaranteed issue around $25,000 to $50,000.
How long does underwriting take with a cancer history?
Cancer histories typically take eight to 12 weeks to underwrite — two to three times longer than a standard application — because carriers request complete treatment records and may consult oncology specialists. Respond quickly to any records requests on your end.
Watch: Getting Covered After a Cancer Diagnosis
This short video from TruStage explains the questions and options that come up when you apply for life insurance after a cancer diagnosis, which map closely to the myeloma underwriting process described above.
Related Reading
- Life Insurance with Anemia (2026)
- Critical Illness Rider: Complete 2026 Guide
- Simplified Issue Life Insurance Explained
- Life Insurance After a Kidney Transplant
Get Your Free Life Insurance Quote
Do not let a multiple myeloma history stop you from protecting your family. Our independent agents work with dozens of carriers and know which ones treat plasma cell disorders most favorably. Request your free, no-obligation life insurance quote today and let us shop your case across the market.
Authoritative Resources
